Erasca Financials
| ERAS Stock | USD 2.70 0.10 3.85% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.22 | 12.2601 |
|
|
Investors should never underestimate Erasca's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Erasca's cash flow, debt, and profitability to make informed and accurate decisions about investing in Erasca Inc.
Net Income |
|
Erasca | Select Account or Indicator |
Understanding current and past Erasca Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Erasca's financial statements are interrelated, with each one affecting the others. For example, an increase in Erasca's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Erasca's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Erasca Inc. Check Erasca's Beneish M Score to see the likelihood of Erasca's management manipulating its earnings.
Erasca Stock Summary
Erasca competes with Lyra Therapeutics, Hookipa Pharma, SAB Biotherapeutics, Cadrenal Therapeutics,, and Coherus BioSciences. Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RASMAPK pathway-driven cancers. The company was incorporated in 2018 and is headquartered in San Diego, California. Erasca operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 123 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US29479A1088 |
| CUSIP | 29479A108 |
| Location | California; U.S.A |
| Business Address | 3115 Merryfield Row, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.erasca.com |
| Phone | 858 465 6511 |
| Currency | USD - US Dollar |
Erasca Key Financial Ratios
| Return On Equity | -0.39 | ||||
| EBITDA | (121.31 M) | ||||
| Net Income | (125.04 M) | ||||
| Cash Per Share | 3.04 X | ||||
| Debt To Equity | 0.07 % |
Erasca Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Erasca's current stock value. Our valuation model uses many indicators to compare Erasca value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Erasca competition to find correlations between indicators driving Erasca's intrinsic value. More Info.Erasca Inc is one of the top stocks in return on equity category among its peers. It is rated # 2 in return on asset category among its peers . At this time, Erasca's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Erasca by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Erasca Inc Systematic Risk
Erasca's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Erasca volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Erasca Inc correlated with the market. If Beta is less than 0 Erasca generally moves in the opposite direction as compared to the market. If Erasca Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Erasca Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Erasca is generally in the same direction as the market. If Beta > 1 Erasca moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Erasca Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Erasca's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Erasca growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Erasca November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Erasca help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Erasca Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Erasca Inc based on widely used predictive technical indicators. In general, we focus on analyzing Erasca Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Erasca's daily price indicators and compare them against related drivers.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 17.38 | |||
| Value At Risk | (5.38) | |||
| Potential Upside | 7.34 |
Additional Tools for Erasca Stock Analysis
When running Erasca's price analysis, check to measure Erasca's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Erasca is operating at the current time. Most of Erasca's value examination focuses on studying past and present price action to predict the probability of Erasca's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Erasca's price. Additionally, you may evaluate how the addition of Erasca to your portfolios can decrease your overall portfolio volatility.